Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 207 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Predicting future breast cancer with precision March 22, 2021 Open Enrollment for 2022 Affordable Care Act Plans is Here! November 1, 2021 The Mediterranean Diet October 30, 2020 Begin Each Day… January 20, 2021 Load more HOT NEWS Women in Science: Celebrating with our Women of Influence initiative EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin and Pembrolizumab A new year of expanding research horizons Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers...
